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ABSTRACT
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma, which may originate 
from impaired differentiation of mesenchymal stem cells (MSC). Expression of MET 
receptor is elevated in alveolar RMS subtype (ARMS) which is associated with worse 
prognosis, compared to embryonal RMS (ERMS). Forced differentiation of ARMS cells 
diminishes MET level and, as shown previously, MET silencing induces differentiation 
of ARMS. In ERMS cells introduction of TPR-MET oncogene leads to an uncontrolled 
overstimulation of the MET receptor downstream signaling pathways. In vivo, 
tumors formed by those cells in NOD-SCID mice display inhibited differentiation, 
enhanced proliferation, diminished apoptosis and increased infiltration of neutrophils. 
Consequently, tumors grow significantly faster and they display enhanced ability to 
metastasize to lungs and to vascularize due to elevated VEGF, MMP9 and miR-378 
expression. In vitro, TPR-MET ERMS cells display enhanced migration, chemotaxis 
and invasion toward HGF and SDF-1. Introduction of TPR-MET into MSC increases 
survival and may induce expression of early myogenic factors depending on the 
genetic background, and it blocks terminal differentiation of skeletal myoblasts. To 
conclude, our results suggest that activation of MET signaling may cause defects in 
myogenic differentiation leading to rhabdomyosarcoma development and progression.
INTRODUCTION
Rhabdomyosarcoma (RMS) is a soft-tissue sarcoma 
that is thought to originate from a defective differentiation 
of muscle progenitor cells or oncogenic transformation 
of mesenchymal stem cells [1]. It affects mainly children 
and adolescents and rarely occurs in adults. Based on 
histological and pathological features of RMS, two major 
subtypes can be distinguished: embryonal (ERMS) and 
alveolar (ARMS) [2]. ARMS tumor is usually associated 
with worse prognosis due to presence of t(2;13) or less 
common t(1;13) translocations, which result in presence 
of either PAX3-FKHR or PAX7-FKHR fusion genes [3].
High aggressiveness of ARMS subtype is also 
associated with increased levels of MET receptor, 
a member of tyrosine kinase receptors family (RTK) [2], 
[4]. The aberrant MET signaling is observed in many 
tumor types [5]. MET receptor responds to only one 
ligand – hepatocyte growth factor (HGF, also known as 
scatter factor, SF). MET receptor overexpression is one of 
the mechanisms that can induce tumor invasive behavior. 
Increased MET expression can originate from MET 
proto-oncogene amplification [6], enhanced transcription 
triggered by other oncogenes like RAS [7] and can be also 
induced by hypoxia [8]. Overexpressed receptors dimerize 
spontaneously and undergo activation even in the absence 
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of HGF [6]. For example, excessive MET expression can 
be observed in some lung cancer cell lines [9] and may be 
used as a prognostic feature in prediction of primary colon 
cancer invasiveness [10].
Interestingly, MET receptor was first discovered 
as the product of TPR-MET oncogene in human 
osteogenic sarcoma cell line. The genetic translocation 
involves translocated promoter region (TPR) encoding 
leucine zipper motif and the MET kinase domain 
with sequence encoding C-terminus [11]. The fusion 
TPR-MET oncoprotein (65 kDa) locates in cytoplasm 
and is constitutively active due to the TPR leucine zipper 
interactions with MET kinase domain. This interaction 
is responsible for dimerization and ligand-independent 
oncogenic activity of TPR-MET [12]. As a consequence, 
the transgenic expression of TPR-MET can cause 
mammary tumors [13].
In vivo, HGF is produced mainly by cells of 
mesenchymal origin while MET receptor is expressed 
mostly on epithelial cells [14]. Nevertheless, cells of 
mesenchymal origin may acquire aberrant expression of 
MET receptor, what activates downstream MET signaling 
pathways and may lead to tumorigenesis [15,16]. This 
mechanism has been demonstrated for liposarcoma [17] 
or leiomyoma [18]. Increased level of the MET receptor 
in tumors of mesenchymal origin is usually associated 
with higher aggressiveness. For example in RMS tumors 
more aggressive ARMS cells display higher expression 
of MET than ERMS cell lines [19]. Increased level 
of the MET receptor in RMS may be explained by the 
defects in posttranscriptional regulation of its expression 
by miR-206 [20, 21].
Recently, we have demonstrated that downregu-
lation of MET receptor in ARMS diminishes tumor 
growth, metastasis [22] and induces myogenic differ-
entiation [23]. The aim of this study was to investigate 
which of the molecular mechanisms associated with 
constitutive activation of MET signaling are respon-
sible for rhabdomyosarcoma development and malig-
nancy. Therefore we constitutively activated MET 
 signaling pathway in ERMS tumors, mesenchymal stem 
cells (MSC) and skeletal myoblasts by introduction of 
TPR-MET  oncogene.
RESULTS
Activation of MET signaling pathways 
blocks myogenic differentiation of embryonal 
rhabdomyosarcoma and promotes tumor growth
Our previous study [19] and current analysis of 
new rhabdomyosarcoma tumor samples demonstrated 
that expression of MET mRNA is lower in embryonal 
(ERMS) than in alveolar (ARMS) subtype (Figure 1A), 
which is usually associated with more malignant 
phenotype [3]. Moreover, in those samples MET 
level positively correlated with MyoD expression 
(Supplementary Table 1), suggesting association of 
MET with a defect in myogenic differentiation in those 
tumors. Accordingly in SMS-CTR and RD ERMS cell 
lines expression of MET was lower than in CW9019, 
RH18, RH28 and RH30 alveolar cell lines (Figure 1B). 
We have previously demonstrated that downregulation of 
MET receptor in ARMS RH30 cell line induces myogenic 
differentiation [22]. In vitro differentiation of several 
ARMS cell lines such as RH30, CW9019 and RH28, 
diminished MET receptor level on the surface of the 
cells (Figure 1C). These results suggest that MET is an 
important factor in myogenic differentiation of RMS.
To determine if activation of MET signaling 
pathways may be responsible for activation of oncogenic 
and metastatic pathways in rhabdomyosarcoma 
development, we transduced SMS-CTR cells 
using lentiviral vectors harboring TPR-MET oncogene. 
TPR-MET was used as a model for constitutive activation 
of downstream MET signaling pathways independent 
of HGF ligand binding. We choose SMS-CTR cell line 
due to its low basal levels of MET receptor (Figure 1B). 
As controls we used SMS-CTR cells transduced with 
GFP. Development of stable cell lines was confirmed 
by incorporation of TPR-MET transgene to genomic 
DNA (Figure 2A) and by expression of TPR-MET 
mRNA (Figure 2B). Accordingly, in TPR-MET cells 
downstream MET signaling pathways were activated, as 
shown by constitutive phosphorylation of AKT kinases, 
regardless of HGF treatment. HGF also further potentiated 
phosphorylation of AKT kinases in TPR-MET cells 
(Figure 2C). Nevertheless, in vitro SMS-CTR cells with 
TPR-MET did not proliferate faster than control cells both 
in standard culture conditions (Figure 2D) and in starving 
conditions nor in hypoxia (Figure 2E). There was also 
no significant effect of TPR-MET on morphology of the 
cells. SMS-CTR cells poorly differentiated in vitro, when 
cultured in DMEM medium with 2% horse serum (data 
not shown). However, when those cells were cultured in 
Matrigel in medium supplemented with 2% horse serum, 
significant morphological changes appeared. Control cells 
acquired elongated shape, whereas SMS TPR-MET cells 
formed rounded colonies, which resembled colonies, 
formed by ARMS RH30 cells displaying high basal MET 
level (Figure 2F).
To investigate this phenomenon further, in vivo 
experiments were performed. Subcutaneous implantation 
of the cells into NOD-SCID immunodeficient mice results 
in their differentiation. The tumor cells acquire a spindle 
shape, which is a feature characteristic for muscle fibers 
(Figure 3A). This effect coincides with upregulation 
of factors regulating myogenic differentiation, such as 
myocyte enhancer factor 2A (MEF2A), myogenin and 
myostatin in tumors in vivo compared to cells in vitro 
(Figure 3B). Similar effect is seen in SMS-CTR cells 
cultured in DMEM medium with 2% horse serum, but 
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it is less potent (Supplementary Figure 1). Interestingly, 
in rhabdomyosarcoma samples, MEF2A level positively 
correlated with myogenin expression, whereas myogenin 
level also positively correlated with myosin heavy chain 2 
(MYH2A), a marker of late differentiation (Supplementary 
Table 1). In our model constitutive activation of MET 
signaling pathways blocked differentiation of the 
tumor cells in vivo, as TPR-MET tumors were formed 
by pleomorphic cells that did not shape into muscle 
fiber-like structures and were characterized by more 
undifferentiated morphology (Figure 3A). This effect may 
be explained by inhibition of expression of myogenic 
markers, such as MEF2A, myogenin and myostatin in 
tumors formed by SMS-CTR cells with constitutively 
active MET signaling (Figure 3C). It also turned out that 
this effect is independent of myomiRs, such as miR-1, 
miR-133a, miR-133b and miR-206, as TPR-MET did 
not regulate them in vivo nor in vitro (Supplementary 
Figure 2A and 2B).
Anaplastic morphology of TPR-MET ERMS tumors 
resembled the morphology of ARMS tumors formed by 
RH30 cells displaying high basal MET level ( Figure 4A). 
Tumors with the constitutively activated MET signaling 
were not only less differentiated than control ERMS 
tumors, but they were also bigger (Figure 4B). They grew 
faster (Figure 4C) and after four weeks they weighed 
more than control tumors (Figure 4D) but less than tumors 
formed by ARMS RH30 cells displaying high basal MET 
level, probably because other genes besides MET are also 
responsible for higher ARMS invasiveness. The effect 
of TPR-MET on tumor growth coincided with enhanced 
proliferation, what was demonstrated by staining for Ki67 
in non-necrotic areas of tumors sections (Figure 5A). The 
staining also revealed that the areas in control tumors with 
Figure 1: Expression of MET receptor is higher in ARMS than in ERMS and it decreases when ARMS cells are 
differentiated. A. Relative expression of MET mRNA compared to GAPDH mRNA was evaluated by qPCR in samples isolated from 
paraffin embedded RMS specimens from patients; n = 4, **p < 0.01. B. Relative expression of MET mRNA compared to GAPDH mRNA 
was evaluated by qPCR in samples from RMS cell lines, n = 3. C. MET receptor level was evaluated by flow cytometry in RH28, CW9019 
and RH30 ARMS cells undifferentiated and differentiated for 7–10 days in DMEM with 2% HS and TPA. Data show one representative 
experiment. Data in graphs are represented as mean +/− SEM.
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Figure 2: Introduction of TPR-MET oncogene to SMS-CTR ERMS cells constitutively activates downstream MET 
signaling pathways. A. Incorporation of TPR-MET transgene to genomic DNA was validated by PCR. The picture shows one 
representative experiment. B. Expression of TPR-MET mRNA was estimated by PCR, n = 2. C. Increased phosphorylation of AKT kinases 
regardless of HGF (20 ng/ml) treatment in TPR-MET cells was demonstrated by Western blotting. The picture shows one representative 
experiment. D. Proliferation of the cells in standard cell culture conditions was calculated by counting of the cells in Burker chamber, 
n = 2. E. Proliferation was estimated with MTT assay in cells cultured in normoxia and at 5% O2 level, 10% FBS and 0.5% BSA, n = 2. 
F. TPR-MET SMS-CTR ERMS cells and RH30 ARMS cells form rounded colonies in Matrigel in medium supplemented with 2% HS in 
contrast to WT and GFP SMS-CTR cells which acquire an elongated phenotype. Data in graphs are represented as mean +/− SEM.
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Figure 3: Activation of MET signaling in SMS-CTR ERMS blocks myogenic differentiation of tumors in vivo.  
A. Hematoxylin-eosin staining showed anaplastic morphology of tumors formed by SMS-CTR cells expressing TPR-MET four weeks after 
subcutaneous implantation of the cells to immunodeficient NOD-SCID mice, whereas control tumors were formed by cells resembling 
muscle fibers. B. Expression of myogenic differentiation markers was evaluated at mRNA level by qPCR in SMS-CTR wild-type cells 
and in paraffin-embedded specimens from tumors formed by SMS-CTR cells after subcutaneous implantation of the cells, n = 4–5. 
C. Constitutive activation of MET signaling in SMS-CTR tumors in NOD-SCID mice inhibits myogenin, myostatin and MEF2A level, 
qPCR, n = 4–5. *p < 0.05, **p < 0.01. Data in graphs are represented as mean +/− SEM.
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the elongated cells resembling muscle fibers displayed 
decreased proliferation (Figure 5A). The opposing 
effect was visible for the apoptotic cells. Staining for 
cleaved PARP (cPARP) revealed its presence in more 
elongated control cells (Figure 5B). Enhanced growth of 
TPR-MET tumor may be explained not only by the 
increased proliferation and decreased apoptosis, but also 
by infiltration of murine neutrophils to those tumors, what 
is demonstrated by Ly6G/6C staining of tumor sections 
(Figure 5C). What is also interesting, due to enhanced 
growth rate, TPR-MET tumors displayed also big necrotic 
areas in the central region of tumors (Supplementary 
Figure 3). Those results suggest that the enhanced tumor 
growth may be associated with inhibition of differentiation 
in vivo and with additional signals provided by tumor 
microenvironment. Accordingly, our previous studies 
demonstrated that RH30 ARMS cells with silenced 
MET level displayed diminished tumor growth and 
metastasis [22, 23].
Activation of MET signaling pathways induces 
angiogenesis, migration and metastasis of 
rhabdomyosarcoma
Hematoxylin-eosin staining of paraffin-embedded 
tumor sections enabled to visualize blood vessels 
containing erythrocytes. It turned out that constitutive 
activation of MET signaling in SMS-CTR cells promoted 
development of capillaries inside tumors, whereas in 
tumors formed by ARMS RH30 cells with decreased 
MET expression (RH30 shMET) after subcutaneous 
implantation into NOD-SCID mice the number of 
capillaries was diminished compared to control RH30 
cells (Figure 6A). Staining for CD31 – a marker of blood 
vessels additionally confirmed that TPR-MET tumors 
display higher number of CD31-positive capillaries 
compared to control tumors (Figure 6B).
Similarly, in vitro TPR-MET SMS-CTR cells 
conditioned media increased the number of junctions, 
Figure 4: Activation of MET signaling in SMS-CTR ERMS cells enhances tumor growth in vivo. A. Hematoxylin-eosin 
staining showed anaplastic morphology of tumors formed by RH30 ARMS cells with high basal MET level after subcutaneous implantation 
of the cells to immunodeficient NOD-SCID mice. B. Photograph of tumors formed by SMS-CTR cells isolated four weeks after subcutaneous 
implantation of the cells into NOD-SCID mice shows their differences in size. C. Tumor size was measured with caliper in different time 
points, n = 7–9. D. SMS-CTR and RH30 tumor weight was evaluated at the end of experiment, n = 4–9. Data in graphs are represented as 
mean +/− SEM.
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Figure 5: Activation of MET signaling in SMS-CTR ERMS cells enhances tumor proliferation, decreases tumor apoptosis 
and induces infiltration of neutrophils in vivo. A. Representative images of the staining for Ki67 in tumor sections show areas of 
tumor cells proliferation. Number of Ki67 positive cells was calculated in non-necrotic areas of tumor specimens, n = 5. Arrows indicate Ki67 
positive cells. B. Representative images of the staining for cleaved PARP demonstrate decreased apoptosis in TPR-MET SMS-CTR tumors. 
C. Representative images of the staining for neutrophils (Ly6G/6C) show infiltration of murine neutrophils to TPR-MET SMS-CTR tumors. 
*p < 0.05, **p < 0.01, ***p < 0.001. Data in graphs are represented as mean +/− SEM. Arrows indicate cPARP positive cells.
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nodes and meshes formed by HUVEC cells in Matrigel 
angiogenic assay (Figure 7A). Those proangiogenic effects 
may be explained by enhanced expression of miR-378a, 
MMP9 and VEGF in SMS-CTR cells expressing TPR-
MET, whereas antiangiogenic capabilities of ARMS cells 
with silenced MET level may be explained by decreased 
expression of those factors (Figure 7B). Moreover, 
inhibition of miR-378a with anti-miR-378a inhibitor 
reversed the effect of TPR-MET on VEGF mRNA and 
protein level (Figure 7C). Those results demonstrate for 
the first time that one of the proangiogenic mediators of 
the MET action may be miR-378.
Enhanced vascularization of TPR-MET tumors 
was accompanied by the induction of metastasis to lungs 
(Figure 8A). Higher metastatic potential may be explained 
by the enhanced migratory capabilities of SMS-CTR cells, 
what was shown in a scratch assay in vitro – migration 
in starving conditions in medium with 0.5% BSA was 
Figure 6: Activation of MET signaling in SMS-CTR ERMS enhances tumor vascularization in vivo, whereas MET 
silencing in RH30 ARMS exerts the opposite effects. A. Activated MET signaling increases number of capillaries in tumors formed 
by SMS-CTR ERMS and RH30 ARMS cells after subcutaneous implantation to NOD-SCID mice. Capillaries with erythrocytes were 
counted after staining of tumor sections for hematoxylin-eosin, n = 7–9. B. Representative images of the staining for CD31 demonstrates 
increased number of capillaries in TPR-MET SMS-CTR tumors in vivo. Number of CD31 positive capillaries was calculated in 
non-necrotic areas of tumor specimens, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001. Data in graphs are represented as mean +/− SEM. 
Arrows indicate the capillaries.
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Figure 7: Activation of MET signaling in SMS-CTR ERMS cells induces proangiogenic effects in vitro by upregulation 
of miR-378, VEGF and MMP9, whereas MET silencing in RH30 ARMS exerts the opposite effects. A. TPR-MET 
SMS-CTR cells conditioned media increase the amount of junctions, nodes and meshes formed by HUVEC cells in Matrigel angiogenesis 
assay in vitro, n = 4. B. Expression of VEGF, MMP9, miR-378a-5p and miR-378–3p is increased in SMS-CTR ERMS cells expressing 
TPR-MET and downregulated in shMET RH30 ARMS cells in vitro, qPCR, n = 2–4. C. Inhibition of miR-378a with anti-miR sequences 
reverses the effect of TPR-MET on VEGF mRNA and protein, n = 2–4. *p < 0.05, **p < 0.01, ***p < 0.001. Data in graphs are represented 
as mean +/− SEM.
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Figure 8: Activation of MET signaling in SMS-CTR ERMS induces metastasis to lungs in vivo and enhances migratory 
and invasive capabilities of the cells in vitro. A. Enhanced metastasis to lungs of SMS-CTR subcutaneous xenotransplants in 
NOD-SCID mice was demonstrated by evaluation of human GAPDH to murine GAPDH mRNA ratio by qPCR, n = 7–9. B. TPR-MET 
expressing cells closed the gap in a scratch assay slightly faster, n = 3. C. In a chemotactic assay TPR-MET expressing cells displayed 
enhanced migration toward HGF (20 ng/ml) and SDF-1 (100 ng/ml), n = 3. D. Representative images of invasion of SMS-CTR cells through 
Matrigel to 10% FBS in vitro show enhanced invasive capabilities of TPR-MET cells. E. TPR-MET SMS-CTR cells display enhanced 
invasion through Matrigel to HGF and SDF1, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001. Data in graphs are represented as mean +/− SEM.
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enhanced in TPR-MET cells (Figure 8B). Due to enhanced 
migratory capabilities those cells displayed also enhanced 
chemotaxis toward gradients of both human HGF and 
SDF-1 in vitro (Figure 8C). Not only chemotaxis, but 
also invasion through Matrigel to FBS (Figure 8D), HGF 
and SDF-1 (Figure 8E) in vitro was strongly enhanced in 
TPR-MET cells.
Activation of MET signaling in mesenchymal 
stem cells induces prolonged survival and may 
drive an oncogenic transformation, and it blocks 
terminal differentiation of skeletal myoblasts
Because one of the hypotheses underlying 
rhabomyosarcoma development states that it may 
originate from a differentiation defect of mesenchymal 
stem cells (MSC), we introduced TPR-MET with viral 
vectors into MSC to constitutively activate MET signaling 
pathways (Figure 9A). Control cells were modified with 
vector harboring GFP. Positive cells were selected with 
blasticidin and cultured for several passages. Control cells 
survived in culture only until the 5th passage and then they 
started to die, whereas TPR-MET MSC survived in culture 
for more than 5 passages (Figure 9B). Surprisingly, in 
MSC expressing TPR-MET, which survived in culture for 
several months, we observed an induction of expression 
of myogenic markers, such as PAX3, PAX7, MYF5, 
MyoD and MRF4 (Figure 9C). MYF5 was the most 
potently upregulated early myogenic factor. Expression of 
osteoblastic RUNX2 and adipogenic PPARG2 negatively 
correlated with SNAI1 expression (Figure 9C). Those 
results suggest that MSC cells expressing MYF5 and 
PAX7 started to differentiate into muscle progenitors. 
Nevertheless, there was no spontaneous differentiation 
towards myoblasts and mature muscle fibers, what 
suggests that those cells were kept in an early stage of 
myogenic differentiation. On the other hand, introduction 
of TPR-MET to human myoblasts (Figure 10A) changed 
their morphology, induced cytotoxicity and blocked 
formation of mature myotubes (Figure 10B), what 
coincided with inhibition of expression of late myogenic 
factors, such as myostatin, myogenin, myosin heavy chain 
and also MEF2A (Figure 10C). Those results indicate that 
for proper terminal differentiation of myoblasts activation 
of MET should be diminished. Our results suggest 
that constitutive activation of MET signaling induces 
prolonged survival of MSC in vitro and may induce early 
myogenic differentiation. Nevertheless, in the future 
more detailed studies are required to demonstrate the 
mechanisms of that process.
DISCUSSION
The salient finding of the present study is that 
constitutive activation of MET signaling by expression 
of TPR-MET oncogene induces rhabdomyosarcoma 
development by blocking myogenic differentiation and 
enhancing proliferation, migration and angiogenesis. 
We have chosen TPR-MET as a model of constitutive 
activation of MET downstream signaling pathways, which 
is independent of HGF ligand binding. Our group [22] 
and others [4] have previously shown that downregulation 
of MET receptor diminishes RMS growth and promotes 
myogenic differentiation of the tumor. In development 
of skeletal muscles MET receptor plays a similar role. 
Constitutive activation of MET signaling by introduction 
of TPR-MET leads to myotube breakdown and muscle 
atrophy [24]. It is in accordance to our studies: activation 
of MET signaling in differentiating human myoblasts was 
cytotoxic, what indicates that in proper terminal myogenic 
differentiation it should be diminished. Moreover, HGF 
and MET are co-localized in activated satellite cells 
in regions of muscle repair [25]. When myoblasts stop 
proliferation and differentiate both MET receptor and HGF 
are downregulated. Introduction of either TPR-MET or 
both HGF and MET receptor inhibits myogenesis at both 
morphological and biochemical levels, as myogenin and 
MyoD levels are diminished [26]. Similarly, in our current 
studies we demonstrated that differentiation of ARMS 
decreases MET receptor levels. In RMS tumors expressing 
TPR-MET we also observed downregulation of myogenic 
markers, such as myogenin, myostatin and MEF2A, what 
explains morphological changes in those tumors. The 
effects of TPR-MET are also independent of myomiRs, 
miRNAs regulating myogenesis, which have previously 
been demonstrated to regulate rhabdomyosarcoma 
development [27].
The significant role of MET signaling pathway in 
RMS differentiation was observed in experiments in vivo, 
whereas in vitro SMS-CTR cells poorly differentiated. One 
of the crucial factors responsible for differentiation in vivo 
may be three dimensional tumor microenvironment. When 
SMS-CTR cells were cultured in a differentiating medium 
in Matrigel instead of conventional two dimensional cell 
culture on plastic dishes, strong effect on morphological 
features was observed. Control SMS-CTR cells became 
more elongated, whereas TPR-MET cells formed rounded 
colonies similar to colonies formed by RH30 ARMS cells, 
which display higher basal MET level. The morphology of 
those cells resembled the morphology of the cells forming 
tumors in mice. It has been previously shown that RMS 
differentiate in spheroids and accumulate the differentiated 
myotube-like cells in the center [28]. Another important 
factor affecting tumor growth and differentiation is 
tumor microenvironment. Murine neutrophils infiltrating 
TPR-MET tumors may modulate both processes. Tumor-
associated neutrophils are usually recruited by tumor in 
response to IL-8 and they have been previously shown 
to function against the host and usually they confer a 
poor prognosis, because they may promote enhanced 
metastasis and vascularization [29]. However, MET 
receptor is expressed not only by cancer cells but also by 
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tumor-associated stromal cells and it is required for the 
recruitment of anti-tumor neutrophils in response to HGF. 
It has been previously shown that MET deletion in mouse 
neutrophils enhances tumor growth and metastasis [30].
Block of differentiation of RMS tumors by 
constitutive activation of MET receptor signaling may 
explain an enhanced proliferation of the tumors, what 
was demonstrated by staining for Ki67 and observation 
of tumor growth. Similarly, in satellite cells MET 
activation inhibits the exit from the cell cycle and 
delays myogenic differentiation [25]. Accordingly MET 
activation diminished apoptosis of tumor cells in vivo, as 
demonstrated by staining for cleaved PARP. Proliferation, 
cell motility and cell survival are regulated by MET via 
AKT pathway [31]. Aberrant phosphorylation of AKT 
kinases was observed in SMS-CTR tumors expressing 
TPR-MET. Constitutive activation of MET signaling 
pathway led to formation of tumors with morphology 
Figure 9: Activation of MET signaling in human mesenchymal stem cells induces prolonged survival and expression of 
myogenic markers. A. MSC were transduced with viral vectors encoding GFP and TPR-MET and selected with blasticidin. Expression 
of TPR-MET transgene at mRNA level was verified by PCR. The picture shows one representative experiment. B. Representative photos 
show morphology of MSC after 3 and 5 passages. After 5 passages control MSC are senescent, whereas TPR-MET MSC still grow. 
C. When TPR-MET MSC were cultured for several months, expression of myogenic factors, such as PAX3, PAX7, MYF5, MyoD 
and MRF4, was induced, whereas expression of osteoblastic RUNX2 and adipogenic PPARG2 factors decreases, what coincided with 
upregulation of SNAI1, qPCR, n = 2. *p < 0.05. Data in graphs are represented as mean +/− SEM.
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resembling ARMS. Nevertheless, ARMS tumors were 
bigger, probably because besides MET also other crucial 
genes may play a role in higher invasiveness, such as 
PAX3-FKHR [3].
In both physiological and pathological conditions 
MET regulates not only proliferation, but also migration 
of the cells toward HGF gradient. In MET deficient 
mice myogenic precursors are unable to migrate from 
the somites to the limbs [32]. Similarly, in pathological 
RMS conditions MET receptor downregulation decreases 
ability of ARMS cells to metastasize [23]. The metastatic 
behavior of RMS cells is regulated by both HGF and 
SDF-1 [33]. Our current studies revealed that constitutive 
activation of MET signaling increased metastasis to lungs 
in murine model, probably due to enhanced migratory 
capabilities of ERMS cells. In vitro, chemotaxis 
and invasion through Matrigel to both human HGF and 
SDF-1 were also elevated. Increased chemotaxis of the 
tumor cells with activated MET signaling may be relevant 
to RMS metastasis in patients.
Tumor progression and dissemination requires the 
development of new blood vessels [34]. In TPR-MET 
ERMS tumors we observed an enhanced vascularization, 
whereas in ARMS with decreased MET level the effect 
was opposite. One of the proangiogenic mediators in 
this process may be VEGF. Upregulation of VEGF by 
Figure 10: Activation of MET signaling in human skeletal myoblasts blocks their growth and terminal differentiation.  
A. Human skeletal myoblasts were transduced with viral vectors encoding GFP and TPR-MET and selected with blasticidin. Expression of 
TPR-MET transgene at mRNA level was verified by PCR. The picture shows one representative experiment. B. Representative photos show 
morphology of human myoblasts after 4 passages. Introduction of TPR-MET induces cytotoxicity, blocks myoblasts growth and terminal 
differentiation. C. TPR-MET myoblasts display decreased expression of late myogenic factors, such as myogenin, myosin heavy chain, 
myostatin and MEF2A, qPCR, n = 2. *p < 0.05, **p < 0.01. Data in graphs are represented as mean +/− SEM.
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HGF-MET has been demonstrated in previous studies in 
different cell types [11]. We hypothesize that miR-378 may 
be one of the mediators of proangiogenic and oncogenic 
actions of MET. miR-378 can promote VEGF expression 
by competing with miR-125a for the same seed region 
in the VEGF 3′UTR [35]. In our studies inhibition of 
miR-378a with anti-miR sequences reversed the effect of 
TPR-MET on VEGF level. miR-378 has been previously 
demonstrated to induce progression and vascularization 
of many tumor types, both of epithelial and mesenchymal 
origin, such as, glioblastoma [36], non-small cell lung 
carcinoma [37] or breast cancer [38]. In case of sarcomas 
miR-378* has been shown to be downregulated in 
osteosarcoma tumor compared to normal osteoblasts [39]. 
In contrary, in rhabdomyosarcoma tumors miR-378 family 
members were demonstrated to be downregulated [40] and 
miR-378 was shown to induce myogenic differentiation 
by increasing the transcriptional activity of MyoD, in part 
by repressing an antagonist MyoR [41]. In our studies we 
have observed only the influence of miR-378 on tumor 
vascularization and no effect on myogenic differentiation, 
probably because our SMS-CTR cell model does not 
display high MyoD expression. Our studies revealed also 
that MMP9 may be an important mediator of the MET 
signaling pathway in RMS development. MMP9 plays 
a central role inangiogenesis, stromal remodeling, and 
consequently metastasis of different tumor types [42].
RMS is a soft tissue tumor, which derives either 
from a defective differentiation of muscle progenitor 
cells or mesenchymal stem cells (MSC) [1]. It has 
been shown previously that expression of TPR-MET in 
differentiating muscles resulted in muscle wasting, but did 
not cause development of musculoskeletal tumors [24]. 
Our current studies demonstrated that introduction of 
MET induces prolonged survival of MSC in cell culture 
in vitro. Moreover, in those cells we detected expression 
of early myogenic factors, such as PAX7, MYF5, MyoD 
and MRF4. Analysis of a hierarchy of transcription factors 
regulating progression through the myogenic lineage [43] 
revealed that those cells resembled rather satellite stem 
cells due to the high level of early myogenic markers, such 
as MYF5 and PAX7. However, we did not observe any 
spontaneous differentiation of those cells into myoblasts or 
mature myofibers. This suggests that constitutive activation 
of MET signaling may drive an oncogenic transformation 
toward sarcoma tumors, but the effect might be dependent 
on genetic background. The hypothesis is strengthen by 
the fact that MSC exposed to pro-longed treatment with 
HGF start to express the markers of the first stages of 
muscle differentiation, whereas they concomitantly loose 
stem cell markers [44]. On the other hand, silencing of 
MET with shRNA impairs MSC differentiation into 
the osteoblastic and chondrogenic lineages [45]. In our 
studies, concomitantly with upregulation of myogenic 
markers, we also observed downregulation of osteoblastic 
RUNX2 and adipogenic PPARG2 marker, probably due 
to upregulation of SNAI1. SNAI1 has been previously 
shown to be a regulator of osteoblastic and adipogenic 
differentiation. MSC cells with silenced SNAI1 level 
prematurely differentiate to osteoblasts or adipocytes [46]. 
During osteoblast differentiation SNAI1 regulates RUNX2 
expression [47], whereas during adipocyte differentiation 
SNAI1 is a regulator of PPARγ expression [48]. Our 
current studies suggest that rhabdomyosarcoma may 
derive from the impaired differentiation of mesenchymal 
stem cells. We have demonstrated for the first time that 
constitutive activation of MET signaling pathway induces 
early myogenic differentiation of MSC. However, 
for development of skeletal muscles and late steps of 
differentiation this signaling needs to be downregulated. 
We suggest that impairment in those differentiation 
steps may lead to RMS development. This hypothesis is 
additionally supported by the fact that transgenic mice 
overexpressing HGF are also predisposed to develop 
RMS with high expression of MET receptor and elevated 
MET kinase activity [49, 50]. Those results strongly 
suggest that autocrine MET signaling broadly promotes 
RMS tumorigenesis. The statement is additionally 
supported by the fact that HGF-MET axis maintains 
cancer stem cells functions in different tumor types, 
such as glioblastoma [51], head and neck squamous 
cell carcinoma [52], pancreatic [53], colon cancer [54] 
or cervical carcinoma [55]. However, additional, more 
detailed studies are required to demonstrate the precise 
mechanism of RMS development. It has to be taken into 
consideration that this effect might be strongly dependent 
on genetic background of the cells. The cooperation of 
TPR-MET with the existing mutations may be crucial 
for induction of myogenic differentiation of MSC and 
possible interactions should be investigated in the future. 
This hypothesis is additionally supported by previous 
studies on MSC tumorigenesis. For example it has been 
shown previously that mouse mesenchymal stem cells 
expressing PAX3-FKHR fusion gene form alveolar 
rhabdomyosarcomas by cooperating with secondary 
mutations [56]. There is also an evidence that deficiency 
of different cell cycle regulators, such as p53, may trigger 
a transformation process in mouse MSC resulting in the 
generation of sarcoma [57].
Taken together, constitutive activation of the MET 
receptor signaling blocks myogenic differentiation of 
RMS and enhances tumor proliferation, vascularization 
and metastasis (Figure 11A). Additionally we postulate 
that aberrant activation of MET signaling may be 
responsible for impairment of myogenic differentiation 
of MSC and as a consequence may lead to oncogenic 
transformation towards ERMS development (Figure 11B). 
In the literature it is postulated that RMS may derive 
from a differentiation defect of either MSC or myogenic 
progenitors [1]. We postulate that origin of RMS may be 
dependent on a subtype of the tumor. ARMS is usually 
associated with presence of PAX3/FKHR or PAX7/FKHR 
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Figure 11: Activation of MET signaling blocks myogenic differentiation and promotes rhabdomyosarcoma development, 
angiogenesis and malignancy. A. Mechanism of a development of malignant tumor by the constitutive activation of the MET receptor 
signaling in ERMS. B. Mechanism of the effect of the aberrant MET receptor activation leading to myogenic differentiation.
fusion genes [3], whereas ERMS does not display their 
expression. Based on our results and on the fact that PAX3 
and PAX7 transcription factors are expressed in satellite 
stem cells [43], we suggest that ERMS may be derived 
from impaired differentiation of MSC. Nevertheless, in the 




RMS cell lines (SMS-CTR, RD, CW9019, 
RH30, RH28, RH18) have been kindly provided 
by Dr. PJ Houghton (Center for Childhood Cancer, 
Columbus, OH, USA) or have been ordered from 
American Type Culture Collection (ATCC, Manassas, 
VA, USA) and they were cultured in DMEM high 
glucose medium (PAA Laboratories GmbH, Pasching, 
Austria / Lonza Group Ltd., Basel, Switzerland) 
supplemented with 10% FBS (PAA / EURx, Gdansk, 
Poland), 50 μg/ml gentamicin (Lonza) at 37°C, 5% CO2 
and 95% humidity. RMS cell lines were differentiated 
in DMEM low glucose medium (PAA / Lonza) 
supplemented with 2% horse serum (HS) (Gibco, BRL 
Grand Island, NY, USA) and 100 nM TPA (Sigma-
Aldrich, St. Louis, MO, USA) for 7–10 days, as described 
previously [23]. For RMS cell culture in Matrigel the 
12-well plate was covered with Matrigel (Corning Life 
Sciences – PZ HTL SA, Warsaw, Poland) and mixed 
with DMEM medium with 2% HS in proportion 1:1. 
Subsequently, 10 000 cells were seeded in Matrigel 
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mixed with medium (with 2% HS) in proportion 1:4 and 
covered with medium with 2% HS. Cells were cultured 
for 7 days and medium was changed every 2–3 days.
Morphology of the cells was assessed using microscope.
Adipose tissue derived mesenchymal stem 
cells (MSC) were isolated by us and characterized as 
described previously [58]. They were cultured in DMEM 
LG (PAA / Lonza) supplemented with 10% FBS for 
mesenchymal stem cells (STEMCELL Technologies 
Inc. Vancouver, BC, Canada), EGF (R&D Systems, 
Minneapolis, MN, USA), PDGF (Becton Dickinson, San 
Jose, CA, USA) and gentamicin.
Human myoblasts were isolated by us and 
characterized as described previously [59]. They were 
cultured in DMEM/F12 (Lonza) supplemented with 
dexamethasone, insulin (both from Sigma-Aldrich) 18% 
FBS, EGF (R&D Systems, Minneapolis, MN, USA), FGF 
(R&D) and HGF (R&D).
Human umbilical vein endothelial cells (HUVEC) 
have been ordered from Becton Dickinson Biosciences. 
They were cultured in M199 medium with HEPES 
(Invitrogen, Carlsbad, CA, USA) supplemented with 
10% FBS (EURx), endothelial cell growth supplement 
(Sigma-Aldrich), heparin (Sigma-Aldrich) and gentamicin 
(Lonza).
Production of viral vectors and 
transduction of cells
Plasmid encoding full length TPR-MET sequence 
was obtained from Addgene (Cambridge, MA, USA) 
and described previously [60]. Viral particles encoding 
GFP (GFP@pLenti6/UbC) and TPR-MET (TprMET@
pLenti6/UbC) were produced using Vira Power Lentiviral 
Expression System (Invitrogen, Carlsbad, CA, USA), 
as described previously [61]. SMS-CTR cells and MSC 
were transduced with lentiviral vectors (at MOI = 10 
and 20 respectively) in presence of 6 μg/ml polybrene 
(Sigma-Aldrich) and subsequently after 72 hours they 
were selected with 2.5 μg/ml blasticidin (InvivoGen, 
Toulouse, France) for two weeks. RH30 ARMS cells were 
transduced with lentiviral vectors encoding shMET and 
shLacZ, as described previously [22], [23].
Transfection of cells with anti-miRs
SMS-CTR cells were transfected with 30 nM 
anti-miR miRNA Inhibitors (Ambion Inc., Austin, 
TX, USA) against miR-378a-5p and miR-378a-3p and 
negative control using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions 72 h before 
the experiments. Subsequently RNA was isolated, as 
described below and cell culture media were collected 
from the cells cultured between 48 and 72 hours after the 
transfection.
Treatment of the cells
SMS-CTR, RH30, RH28 and CW9019 cells were 
subjected to differentiation in DMEM (Lonza) with 
2% horse serum (HS) (Gibco BRL) and with or without 
100 nM TPA (Sigma-Aldrich) [23]. For evaluation of the 
phosphorylation level of AKT kinases, the SMS-CTR cells 
were seeded at density of 120 000 cells per well on 6-well 
plate. After 24 hours medium was changed for DMEM with 
0.5% BSA. Next day, the cells were treated with 20 ng/
ml HGF in fresh starving medium for 10 minutes at 37°C. 
Subsequently, protein was isolated, as described below.
Flow cytometry
For evaluation of MET receptor level RMS cells were 
stained with monoclonal FITC-labeled anti-human HGFR/
c-MET antibody, clone 95106 (R&D) or mouse IgG1 
isotype control (R&D) and the results were analyzed using 
FACS Canto cytometer (Becton Dickinson) FACS Diva 
software (Becton Dickinson), as described previously [23].
DNA and RNA isolation and reverse 
transcription
Genomic DNA was isolated using QIAmp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany) according 
to vendor’s protocol. The total RNA was extracted using 
Universal RNA purification Kit (EURx), according to 
vendor’s protocol. For analysis of miRNA expression, 
total RNA was isolated with mirVana miRNA Isolation Kit 
(Ambion Inc., Austin, TX, USA). Total RNA from paraffin 
embedded tumor samples was isolated with RecoverAll™ 
Total Nucleic Acid Isolation Kit (Ambion). The reverse 
polymerase transcription of mRNA was performed using 
MMLV reverse transcriptase (Promega, Madison, WI, 
USA) according to the manufacturer’s protocol. Reverse 
transcription of miRNA was performed with NCode VILO 
miRNA cDNA Synthesis Kit (Invitrogen), according to the 
vendor’s protocol.
PCR
Incorporation of TPR-MET transgene into 
genomic DNA was validated by PCR with a forward 
primer 5′-TGGACAATGATGGCAAGAAA-3′ and a 
reverse primer 5′-GAAGTGGATGGCTTTGGAAA-3′ 
using Taq PCR Master Mix (EURx), according to 
vendor’s protocol. Expression of TPR-MET mRNA 
was evaluated by PCR with a forward primer 
5′-GAGCCAATTTACAAGAACAAAGGA-3′ and reverse 
primer 5′-ATACTGCACTTGTCGGCATGAA-3′.
Quantitative real-time PCR
Gene expression was determined by qRT-PCR 
analysis on ABI PRISM 7300 Sequence Detection 
Oncotarget31394www.impactjournals.com/oncotarget
System (Applied Biosystems, Foster City, CA, USA) 
using Blank qPCR Master Mix (EURx) and the following 
Taq-Man probes (Applied Biosystems): human: 
GAPDH (Hs99999905_m1), MET (Hs01565589_m1), 
VEGF (Hs00173626_m1), MMP9 (Hs00234579_m1), 
MYF5 (Hs00271574_m1), MYOD (Hs00159528_m1), 
MRF4 (Hs01547104_g1), MEF2A (Hs01050409_m1), 
MYOSTATIN (Hs00976237_m1), MYOGENIN 
(Hs01032275_m1), MYH2 (Hs00430042_m1), PAX3 
(Hs00240950_m1), PAX7 (Hs00242962_m1), SNAI1 
(Hs00195591_m1), RUNX2 (Hs00231692_m1), 
PPARG2 (Hs01115513_m1) and mouse: GAPDH 
(Mm99999915_g1).
For evaluation of miRNA expression by quantitative 
real-time PCR Sybr Green qPCR Master MIX (EURx) 
and universal reverse primer from NCode VILO miRNA 
cDNA Synthesis Kit (Invitrogen) were used with the 
following forward primers:












The mRNA expression level for all samples was 
normalized to the housekeeping gene GAPDH, whereas 
miRNA level was normalized to the housekeeping 
U6 snRNA level. Expression levels of miRNA and genes 
were quantified employing the 2 −ΔΔCt calculation or 
2 −ΔCt using U6 snRNA or GAPDH a housekeeping 
controls.
Analysis of protein (Western blotting and ELISA)
Protein was isolated with M-PER lysing buffer 
(Pierce, Rockford, IL, USA) and Western blot was 
done with anti-GAPDH rabbit mAb (Cell Signaling), 
anti-phospho-Akt (Ser473) rabbit mAb (Cell Signaling, 
Danvers, MA, USA), as described previously [22, 23]. 
ELISA for VEGF (R&D Systems) in media collected 
from the transfected cells was performed according to the 
vendor’s protocol.
Migration, chemotaxis and invasion 
through Matrigel
Confluent SMS-CTR cells were treated with DMEM 
medium with 0.5% BSA for 24 hours. Subsequently, a 
scratch was generated with a pipette tip. Starving medium 
was replaced every day. Photographs were analyzed 
using ImageJ software (National Institute of Health). 
Chemotaxis of cells to 20 ng/ml HGF (R&D System) 
and 100 ng/ml SDF-1 (Peprotech, Rocky Hill, NJ, USA) 
was evaluated using modified Boyden’s chamber with 
8 μm pore polycarbonate membrane inserts (Transwell; 
Corning Life Sciences – PZ HTL SA, Warsaw, Poland), 
as described previously [23]. 0.5% BSA DMEM medium 
was used as a negative control, whereas 10% FBS as a 
positive control. Similarly invasion of SMS-CTR cells 
through growth factor reduced Matrigel invasion inserts 
(Corning Life Sciences – PZ HTL SA, Warsaw, Poland) 
to 10% FBS, 20 ng/ml HGF, 100 ng/ml SDF-1, 0.5% BSA 
was also investigated, as described previously [23], using 
density of 5.0 × 104 in 0.5 ml per one insert. Invasion of 
the cells treated with 20 ng/ml HGF was also investigated.
Proliferation and mitochondrial activity
SMS-CTR cells were seeded on 24-well plates at 
density of 10 000 cells per well. After 24 hours medium 
was changed and 24, 48 and 72 hours later cells counted 
in a Burker hemocytometer chamber. To examine 
mitochondrial activity of the cells MTT test was done. 
2000 of SMS-CTR cells were seeded on 96-well plates. 
After 24 hours medium was changed for either a medium 
with 10% FBS or 0.5% BSA and cells were incubated 
either in normoxia (21% O2 level) or at 5% O2 level for 24 
hours. Afterwards mitochondrial activity of the cells was 
estimated with CellTiter 96® AQueous One Solution assay 
(Promega), according to vendor’s protocol.
Angiogenic Matrigel assay in vitro
SMS-CTR cell lines were cultured on six- 
well-plates for 24 h in DMEM media with 2% FBS 
at 5% O2 level. Subsequently, the conditioned media 
were collected, and they were mixed with M199 medium 
with 2% FBS in a proportion of 1:1. For Matrigel assay, 
50 μl of growth factor reduced Matrigel (BD Biosciences) 
was plated in a 96-well plate and incubated at 37°C for 
30 min. HUVEC were detached, counted, and single-cell 
suspensions at a density of 10,000 cells per well in 200 μl 
of conditioned media and proper controls were plated on 
the Matrigel. Subsequently, endothelial tube formation 
was photographed 6 h after seeding. Formation of tubule-
like structures was analyzed with Angiogenesis Analyzer 
for ImageJ (Carpentier G., Angiogenesis Analyzer for 
ImageJ (2012) available online: http://imagej.nih.gov/ij/
macros/toolsets/Angiogenesis%20Analyzer.txt).
Microscopy
Microscopic images were visualized with Oympus 
IX70 or Olympus BX51 microscopes (Olympus 
Corporation, Tokyo, Japan) and Canon EOS1100D digital 




5 × 106 SMS-CTR and RH30 cells were injected 
subcutaneously into 6–8 weeks old NOD-SCID mice. 
Each experimental group comprised 4–5 animals and all 
the experiments were repeated two times. Tumor size was 
evaluated two times per week with a caliper and tumor 
volume was estimated with a formula V=D × d2 × 0.5 (V is 
the tumor volume, D is the biggest dimension; d is the 
smallest dimension). After 4 weeks the mice were killed 
and their tumors and bone marrow cells were harvested. 
After evaluation of tumor weight, they were fixed in 
formalin. Tumor sections were stained with hematoxylin-
eosin to visualize tumor morphology and capillaries 
with erythrocytes inside them and after deparaffinization 
they were stained immunohistochemically, as described 
previously [23], with anti-Ki67 primary mouse monoclonal 
antibody to evaluate tumor proliferation (clon MIB-1; 
1 : 75, DakoCytomation, Denmark, UK), anti-cleaved 
PARP (1:100, Abcam, Cambridge UK; ab32064) to 
visualize apoptosis and anti-CD31 antibody to visualize 
tumor vascularization (1:50, Abcam, ab28364). The 
sections were also stained immunofluorescently with anti-
Ly6G/6C primary antibody to visualize murine neutrophils 
infiltrating tumor (clone RB6–8C5, 1:100, Biolegend, San 
Diego, California, USA) and subsequently with secondary 
goat anti-rat antibody conjugated with Alexa Fluor 555 
(1:300, Life Technologies, Warsaw, Poland) and finally 
the slides were mounted in Vectashield Mounting Medium 
with DAPI (Vector Laboratories, Inc, Burlingame, CA, 
USA) The metastasis of SMS-CTR cells to the bone 
marrow was evaluated by real-time PCR using human 
GAPDH specific primers-probe set (Hs99999905_m1; 
Applied Biosystems) compared to murine GAPDH 
(Mm99999915_g1; Applied Biosystems). Expression of 
genes and miRNAs was evaluated in paraffin-embedded 
tumor samples, as described in previous section.
Ethics statement
Human experiments were approved by the Local 
Bioethical Committee of the Collegium Medicum 
of the Jagiellonian University in Krakow, Poland 
(no. KBET/32/B/2014). Biopsies of rhabdomyosarcoma 
tumors were collected during routine surgery for 
preparation of paraffin-embedded samples and analysis 
of gene expression. Animal experiments were approved 
by I Local Ethics Committee in Krakow (no. 89/2009, 
23/2013).
Statistical analysis
Unless stated otherwise, results show mean +/− SEM 
of at least 2–4 independent experiments. Statistical analysis 
was performed by one-way ANOVA with Tukey post-test 
or student’s t-test. Differences with a value of p < 0.05 were 
considered statistically significant. Correlations between 
genes in patients were calculated as Pearson’s correlations.
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